BDNF insufficiency exacerbates ALS progression.

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron loss.
• The role of neurotrophic factors, like brain-derived neurotrophic factor (BDNF), in ALS pathogenesis is suspected but lacks direct evidence.

Purpose of the Study:

• To investigate the impact of BDNF insufficiency on ALS progression.
• To evaluate the therapeutic potential of activating the BDNF-TrkB pathway in ALS models.

Main Methods:

• Analysis of BDNF val/met mutation in ALS patient cohorts.
• Utilizing a FUS^R521C knockin mouse model to study BDNF haploinsufficiency.
• Administering an agonistic antibody targeting the BDNF receptor TrkB in ALS mouse models.

Main Results:

• A BDNF val/met mutation correlated with reduced survival time in ALS patients.
• BDNF haploinsufficiency in mice led to shortened lifespan, accelerated motor deficits, and increased motor neuron death.
• TrkB activation by antibody treatment rescued ALS phenotypes and demonstrated superior efficacy over riluzole in mouse models.

Conclusions:

• Insufficient BDNF is a significant factor in ALS progression.
• Targeting the BDNF-TrkB pathway offers a promising therapeutic strategy for ALS treatment.